On this page
FMO3
flavin containing dimethylaniline monoxygenase 3
The FMO3 gene provides instructions for an enzyme primarily involved in metabolising nitrogen-containing compounds, including trimethylamine, and plays a role in drug processing. The FMO3 gene encodes flavin-containing dimethylaniline monoxygenase 3, an enzyme crucial for breaking down nitrogenous substances in the body, primarily in the liver.
FMO3 is located on the long (q) arm of chromosome 1, at band 1q24.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 1 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The FMO3 gene, or flavin containing dimethylaniline monoxygenase 3, is a crucial component of the body's metabolic system. It belongs to a family of enzymes responsible for processing compounds containing nitrogen, sulphur, or phosphorus. This gene is particularly important for its role in detoxifying dietary compounds in the liver.
The FMO3 enzyme helps to convert odorous substances, such as trimethylamine, into odourless forms that can be excreted. Additionally, research suggests FMO3 is involved in the metabolism of various drugs, impacting how individuals respond to certain medications.
What the gene does
The FMO3 gene provides the blueprint for an enzyme predominantly active in the liver. This enzyme is part of the flavin-containing dimethylaniline monooxygenase (FMO) family, which collectively metabolise a range of chemical compounds. FMO3 specifically targets nitrogen-containing substances derived from the diet.
One of the primary functions of the FMO3 enzyme is to break down trimethylamine, a compound produced by gut bacteria during the digestion of certain foods like eggs, legumes, and specific types of fish. Trimethylamine is characterised by a strong, fishy smell. FMO3 converts this odorous compound into trimethylamine-N-oxide, which is odourless and subsequently eliminated from the body via urine. Beyond this, FMO3 is thought to participate in the metabolism of several medications, including some anticancer drugs, anti-inflammatory agents, antifungals, and antidepressants, as well as nicotine.
Video: Genetics 101
Chromosome location
The FMO3 gene is situated on chromosome 1, specifically at position 1q24.3. This location indicates its precise address within the human genome, residing on the long arm of chromosome 1. The gene's presence at this band suggests its genetic neighbourhood relative to other genes on the chromosome.
Protein structure
The FMO3 protein consists of 532 amino acids. Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Genetic variations, or variants, within the FMO3 gene can impact the enzyme's ability to function correctly. Over 40 distinct variants have been identified that are associated with altered FMO3 activity. These changes can range from small alterations in the protein's building blocks, amino acids, to variants that result in a shortened, non-functional enzyme. The nature of these variants can influence the severity of associated conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1045G>T | p.Glu349Ter | Pathogenic | ★★☆☆ | Trimethylaminuria |
c.1118dup | p.Ser374fs | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.1139_1140del | p.Pro380fs | Pathogenic/Likely pathogenic | ★★☆☆ | FMO3-related disorder |
c.1164G>A | p.Trp388Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.1183+1del | - | Pathogenic/Likely pathogenic | ★★☆☆ | FMO3-related disorders |
c.1262G>T | p.Gly421Val | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.1498C>T | p.Arg500Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.155_191delinsTCCATCACAGGACCATGC | p.Ala52fs | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.237del | p.Asn80fs | Pathogenic/Likely pathogenic | ★★☆☆ | Trimethylaminuria |
c.692G>A | p.Trp231Ter | Pathogenic | ★★☆☆ | Trimethylaminuria |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the FMO3 gene are primarily associated with Trimethylaminuria, commonly known as fish odour syndrome. This condition is inherited in an autosomal recessive (AR) pattern, meaning an individual must inherit two copies of a pathogenic FMO3 variant (one from each parent) to develop the condition. When the FMO3 enzyme is deficient or non-functional, trimethylamine accumulates in the body, leading to a strong body odour resembling rotten fish.
- Trimethylaminuria (fish odour syndrome) Dedicated page coming soon
Inheritance pattern
Conditions caused by pathogenic FMO3 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
In the UK, the FMO3 gene is recognised within NHS Genomic Medicine Service pathways. It is included on the "Likely inborn error of metabolism" green panel (R98) and the "Undiagnosed metabolic disorders" green panel in NHS England's National Genomic Test Directory. This indicates its importance in the clinical assessment of individuals with suspected metabolic conditions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the main function of the FMO3 gene?
The FMO3 gene provides instructions for an enzyme that primarily breaks down nitrogen-containing compounds, such as trimethylamine, into odourless forms in the liver. It also plays a role in metabolising various medications.
What is trimethylaminuria?
Trimethylaminuria, or fish odour syndrome, is a condition caused by a deficiency in the FMO3 enzyme. This leads to an accumulation of trimethylamine in the body, resulting in a distinct fishy body odour.
How is trimethylaminuria inherited?
Trimethylaminuria is inherited in an autosomal recessive pattern. This means an individual must inherit two copies of a variant FMO3 gene, one from each parent, to be affected by the condition.
References
- Koukouritaki SB, Poch MT, Henderson MC. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. The Journal of pharmacology and experimental therapeutics. 2007. PMID: 17050781
- Zhou J, Shephard EA. Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutation research. 2006. PMID: 16481213
- Krueger SK, Vandyke JE, Williams DE. The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug metabolism reviews. 2006. PMID: 16684653
- Bain MA, Fornasini G, Evans AM. Trimethylamine: metabolic, pharmacokinetic and safety aspects. Current drug metabolism. 2005. PMID: 15975041
- Zhang J, Tran Q, Lattard V. Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria. Pharmacogenetics. 2003. PMID: 12893987
- Hernandez D, Addou S, Lee D. Trimethylaminuria and a human FMO3 mutation database. Human mutation. 2003. PMID: 12938085
- Zschocke J, Kohlmueller D, Quak E. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet (London, England). 1999. PMID: 10485731
- Mitchell SC. Trimethylaminuria: susceptibility of heterozygotes. Lancet (London, England). 1999. PMID: 10609842
- Dolphin CT, Janmohamed A, Smith RL. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nature genetics. 1997. PMID: 9398858